Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis
Tania Jain(Johns Hopkins University), Jeanne Palmer(Mayo Clinic in Florida), Nandita Khera(Mayo Clinic in Florida), Katie L. Kunze(Mayo Clinic in Arizona), M’hamed Temkit(Phoenix Children's Hospital), Mrinal M. Patnaik(Mayo Clinic in Arizona), William J. Hogan(Mayo Clinic), Vivek Roy(Jacksonville College), Pierre Noël(Mayo Clinic Hospital), Lisa Z. Sproat(Mayo Clinic Hospital), James L. Slack(Memorial Sloan Kettering Cancer Center), José F. Leis(Mayo Clinic), Daniel K. Partain(Brigham and Women's Hospital), Veena Fauble(Mayo Clinic in Arizona), Ruben A. Mesa(The University of Texas MD Anderson Cancer Center)
Cited by 46
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2019|735